1J5 Stock Overview
Operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Hyphens Pharma International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.29 |
| 52 Week High | S$0.30 |
| 52 Week Low | S$0.26 |
| Beta | 0.28 |
| 11 Month Change | 1.72% |
| 3 Month Change | 5.36% |
| 1 Year Change | 5.36% |
| 33 Year Change | -1.67% |
| 5 Year Change | 51.28% |
| Change since IPO | 7.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1J5 | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | 1.7% | -1.3% | -0.6% |
| 1Y | 5.4% | 13.2% | 9.5% |
Return vs Industry: 1J5 underperformed the SG Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: 1J5 underperformed the SG Market which returned 9.5% over the past year.
Price Volatility
| 1J5 volatility | |
|---|---|
| 1J5 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in SG Market | 15.6% |
| 10% least volatile stocks in SG Market | 2.5% |
Stable Share Price: 1J5 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: 1J5's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 431 | See Wah Lim | www.hyphensgroup.com |
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, family medicine, and general surgery. The Proprietary Brands segment develops, markets, and sells dermatological products and health supplement products.
Hyphens Pharma International Limited Fundamentals Summary
| 1J5 fundamental statistics | |
|---|---|
| Market cap | S$91.12m |
| Earnings (TTM) | S$10.42m |
| Revenue (TTM) | S$195.53m |
8.7x
P/E Ratio0.5x
P/S RatioIs 1J5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1J5 income statement (TTM) | |
|---|---|
| Revenue | S$195.53m |
| Cost of Revenue | S$128.02m |
| Gross Profit | S$67.52m |
| Other Expenses | S$57.10m |
| Earnings | S$10.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.034 |
| Gross Margin | 34.53% |
| Net Profit Margin | 5.33% |
| Debt/Equity Ratio | 5.7% |
How did 1J5 perform over the long term?
See historical performance and comparison